Product Name: AFAP1L2 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC-P, WB
Applications: AFAP1L2 antibody can be used for detection of AFAP1L2 by Western blot at 1 – 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: AFAP1L2 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human AFAP1L2.The immunogen is located within the last 50 amino acids of AFAP1L2.
Host Species: Rabbit
Purification: AFAP1L2 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 1080645-95-9
Product: KX2-391 (Mesylate)
Buffer: AFAP1L2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: AFAP1L2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: AFAP1L2 Antibody: XB130, KIAA1914, CTB-1144G6.4, XB130, Actin filament-associated protein 1-like 2, AFAP1-like protein 2
Accession NO.: NP_001001936
Protein Ino: 50897850
Official Symbol: AFAP1L2
Geneid: 84632
Background: AFAP1L2 Antibody: AFAP1L2, also known as XB130, is structurally similar to actin-filament-associated protein (AFAP), containing several SH2- and SH3-binding motifs, two pleckstrin homology domains, a coiled-coil region, and many potential phosphorylation sites. It interacts with and is phosphorylated by c-Src tyrosine kinase. Suppression of AFAP1L2 via siRNA reduced Src activity, IL-8 production, EGF-induced phosphorylation of Akt and GSK3beta, and altered cell cycles in human lung epithelial cells suggesting that AFAP1L2 plays a role as an adaptor in the regulation of Src signal transduction and multiple cellular functions. Recent experiments have shown that AFAP1L2 is highly expressed in thyroid and is the substrate RET/PTC kinase, a thyroid-specific kinase that plays a pathogenic role in papillary thyroid cancer. Down-regulation of AFAP1L2 in these cancer cells reduced Akt activity, inhibiting cell-cycle progression and cancer cell survival in suspension, indicating that AFAP1L2 may be a valuable target in thyroid cancer therapy. At least four isoforms of AFAP1L2 are known to exist.
PubMed ID:http://aac.asm.org/content/52/5/1686.abstract
